Dr. Luke is an internationally recognized investigator in developmental cancer therapeutics, particularly immunotherapies, where he has led clinical trials ranging from the Phase III Keynote-716 trial of pembrolizumab in stage II melanoma to Phase I studies of novel therapeutics covering checkpoint inhibitors, innate immune stimulators, adoptive cell transfer and immuno-metabolism approaches, among others. Dr. Luke received his M.D. from the Rosalind Franklin University of Medicine and Science and then trained at Boston University Medical Center and Memorial-Sloan-Kettering Cancer Center. He subsequently has held faculty positions at Dana-Farber Cancer Institute, the University of Chicago and currently the University of Pittsburgh. Dr. Luke’s translational research is focused on application of large-scale informatics to advance cancer immunotherapy and he has been a lead investigator for clinical trials of numerous novel immunotherapy agents. Dr. Luke has received research support and/or professional awards from the NCI, DOD, ASCO and multiple professional or private societies.